Pathophysiology and disease progression of atrial fibrillation: Importance of achieving and maintaining sinus rhythm

Journal of Cardiovascular Electrophysiology

Volumn 19, Issue 8, 2008, Pages 885-890

  Cohen, Marc ^a   Naccarelli, Gerald V ^b  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Antiarrhythmia agents; Atrial fibrillation; Disease progression; Ion channels; Pathophysiology; Rhythm control

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AAP 10; AMIODARONE; ANTIARRHYTHMIC AGENT; AVE 1231; AZIMILIDE; CELL PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNEXIN 40; DOFETILIDE; DRONEDARONE; FLECAINIDE; GELATINASE A; GELATINASE B; GLYCOGEN; GSMTX4; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDE; PROPAFENONE; ROTIGAPTIDE; SOTALOL; TEDISAMIL; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VERNAKALANT;

APOPTOSIS; CARDIOMYOPATHY; CATHETER ABLATION; CELL DEGENERATION; CELL SIZE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FIBROSING ALVEOLITIS; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART CONTRACTION; HEART MUSCLE FIBROSIS; HUMAN; MYOCARDITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SARCOPLASMIC RETICULUM; SINUS RHYTHM;

ATRIAL FIBRILLATION; DISEASE PROGRESSION; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MODELS, CARDIOVASCULAR;

EID: 47849127907     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2008.01134.x     Document Type: Review

References (71)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE : Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and RIsk factors in Atrial fibrillation (ATRIA) study. JAMA 2001 285 : 2370 2375.
2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S : ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006 27 : 1979 2030.
3. Schoonderwoerd BA, Van Gelder IC, Van Veldhuisen DJ, Van den Berg MP, Crijns HJ : Electrical and structural remodeling: Role in the genesis and maintenance of atrial fibrillation. Prog Cardiovasc Dis 2005 48 : 153 168.
4. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL, Hammill SC, Shen WK, Gersh BJ : Long-term progression and outcomes with aging in patients with lone atrial fibrillation: A 30-year follow-up study. Circulation 2007 115 : 3050 3056.
5. Shiroshita-Takeshita A, Brundel BJ, Nattel S : Atrial fibrillation: Basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 2005 13 : 181 193.
6. Van Gelder IC, Hemels ME : The progressive nature of atrial fibrillation: A rationale for early restoration and maintenance of sinus rhythm. Europace 2006 8 : 943 949.
7. Brundel BJ, Van Gelder IC, Henning RH, Tieleman RG, Tuinenburg AE, Wietses M, Grandjean JG, Van Gilst WH, Crijns HJ : Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001 103 : 684 690.
8. Allessie M, Ausma J, Schotten U : Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002 54 : 230 246.
9. Nattel S : New ideas about atrial fibrillation 50 years on. Nature 2002 415 : 219 226.
10. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA : Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995 92 : 1954 1968.
11. Brundel BJ, Henning RH, Kampinga HH, Van Gelder IC, Crijns HJ : Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002 54 : 315 324.
12. Brugada R : Molecular biology of atrial fibrillation. Minerva Cardioangiol 2004 52 : 65 72.
13. Thiedemann KU, Ferrans VJ : Left atrial ultrastructure in mitral valvular disease. Am J Pathol 1977 89 : 575 604.
14. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A : Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997 96 : 1180 1184.
15. Aimé-Sempé C, Folliguet T, Rücker-Martin C, Krajewska M, Krajewska S, Heimburger M, Aubier M, Mercadier JJ, Reed JC, Hatem SN : Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999 34 : 1577 1586.
16. Corradi D, Callegari S, Benussi S, Nascimbene S, Pastori P, Calvi S, Maestri R, Astorri E, Pappone C, Alfieri O : Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. Virchows Arch 2004 445 : 498 505.
17. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H, Dhein S : Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004 90 : 400 405.
18. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, Ishida M, Shingu T, Sueda T, Yoshizumi M, Chayama K : Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004 43 : 818 825.
19. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, Sen L : Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004 109 : 363 368.
20. Cha YM, Redfield MM, Shen WK, Gersh BJ : Atrial fibrillation and ventricular dysfunction: A vicious electromechanical cycle. Circulation 2004 109 : 2839 2843.
21. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 : 1825 1833.
22. Wyse DG : Rate control vs rhythm control strategies in atrial fibrillation. Prog Cardiovasc Dis 2005 48 : 125 138.
23. Curtis AB, Gersh BJ, Corley SD, DiMarco JP, Domanski MJ, Geller N, Greene HL, Kellen JC, Mickel M, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG : Clinical factors that influence response to treatment strategies in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005 149 : 645 649.
24. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG : Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004 109 : 1509 1513.
25. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell WB, Havranek E, Murray K, Olshansky B, O'Neill G, Sami M, Schmidt S, Storm R, Zabalgoitia M, Miller J, Chandler M, Nasco EM, Greene HL : Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004 109 : 1973 1980.
26. Sherman DG, Kim SG, Boop BS, Corley SD, DiMarco JP, Hart RG, Haywood LJ, Hoyte K, Kaufman ES, Kim MH, Nasco E, Waldo AL : Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 2005 165 : 1185 1191.
27. Chung MK, Shemanski L, Sherman DG, Greene HL, Hogan DB, Kellen JC, Kim SG, Martin LW, Rosenberg Y, Wyse DG : Functional status in rate- versus rhythm-control strategies for atrial fibrillation: Results of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol 2005 46 : 1891 1899.
28. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ : A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002 347 : 1834 1840.
29. Rienstra M, Van Gelder IC, Hagens VE, Veeger NJ, Van Veldhuisen DJ, Crijns HJ : Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: A subanalysis of the RACE study. Eur Heart J 2006 27 : 357 364.
30. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C : Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001 104 : 292 296.
31. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U : Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003 41 : 1690 1696.
32. Vora A, Karnad D, Goyal V, Naik A, Gupta A, Lokhandwala Y, Kulkarni H, Singh BN : Control of heart rate versus rhythm in rheumatic atrial fibrillation: A randomized study. J Cardiovasc Pharmacol Ther 2004 9 : 65 73.
33. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN : Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998 98 : 2574 2579.
34. Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN : Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996 94 : 1585 1591.
35. Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquie JL, Scavee C, Bordachar P, Clementy J, Haissaguerre M : Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004 351 : 2373 2383.
36. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P : Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 2004 126 : 476 486.
37. Hagens VE, Van Veldhuisen DJ, Kamp O, Rienstra M, Bosker HA, Veeger NJ, Tijssen JG, Crijns HJ, Van Gelder IC : Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: Results from the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm 2005 2 : 19 24.
38. Brignole M, Menozzi C, Gasparini M, Bongiorni MG, Botto GL, Ometto R, Alboni P, Bruna C, Vincenti A, Verlato R : An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J 2002 23 : 892 900.
39. KAch class Ic drugs and beta blockers in pigs. Med Sci Monit 2004 10 : BR221 BR228.
40. Bachmann A, Gutcher I, Kopp K, Brendel J, Bosch RF, Busch AE, Gögelein H : Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 2001 364 : 472 478.
41. Wirth KJ, Brendel J, Steinmeyer K, Linz DK, Rutten H, Gögelein H : In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J Cardiovasc Pharmacol 2007 49 : 197 206.
42. Decher N, Kumar P, Gonzalez T, Pirard B, Sanguinetti MC : Binding site of a novel Kv1.5 blocker: A "foot in the door" against atrial fibrillation. Mol Pharmacol 2006 70 : 1204 1211.
43. Gögelein H, Brendel J, Steinmeyer K, Strubing C, Picard N, Rampe D, Kopp K, Busch AE, Bleich M : Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol 2004 370 : 183 192.
44. Persson F, Carlsson L, Duker G, Jacobson I : Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Pharmacol 2005 46 : 7 17.
45. Persson F, Carlsson L, Duker G, Jacobson I : Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J Cardiovasc Electrophysiol 2005 16 : 329 341.
46. Persson F, Andersson B, Duker G, Jacobson I, Carlsson L : Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre. Eur J Pharmacol 2007 558 : 133 143.
47. Fedida D : Vernakalant (RSD1235): A novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 2007 16 : 519 532.
48. 2+-exchange. Cardiovasc Res 2007 73 : 37 47.
49. Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD : New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther 2007 5 : 707 714.
50. Bode F, Sachs F, Franz MR : Tarantula peptide inhibits atrial fibrillation. Nature 2001 409 : 35 36.
51. Singh BN, Sarma JS : Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias. J Cardiovasc Pharmacol Ther 2001 6 : 69 87.
52. Castro A, Bianconi L, Santini M : New antiarrhythmic drugs for the treatment of atrial fibrillation. Pacing Clin Electrophysiol 2002 25 : 249 259.
53. Khan MH : Oral class III antiarrhythmics: What is new? Curr Opin Cardiol 2004 19 : 47 51.
54. Singh S : Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. J Interv Card Electrophysiol 2004 10 (Suppl 1 71 76.
55. Kathofer S, Thomas D, Karle CA : The novel antiarrhythmic drug dronedarone: Comparison with amiodarone. Cardiovasc Drug Rev 2005 23 : 217 230.
56. Doggrell SA : Tedisamil: Master switch of nature? Expert Opin Investig Drugs 2001 10 : 129 138.
57. Dhein S, Larsen BD, Petersen JS, Mohr FW : Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern. Cell Commun Adhes 2003 10 : 371 378.
58. Clarke TC, Thomas D, Petersen JS, Evans WH, Martin PE : The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin43. Br J Pharmacol 2006 147 : 486 495.
59. Stahlhut M, Petersen JS, Hennan JK, Ramirez MT : The antiarrhythmic peptide rotigaptide (ZP123) increases connexin43 protein expression in neonatal rat ventricular cardiomyocytes. Cell Commun Adhes 2006 13 : 21 27.
60. Axelsen LN, Stahlhut M, Mohammed S, Larsen BD, Nielsen MS, Holstein-Rathlou NH, Andersen S, Jensen ON, Hennan JK, Kjølbye AL : Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123). J Mol Cell Cardiol 2006 40 : 790 798.
61. Müller A, Gottwald M, Tudyka T, Linke W, Klaus W, Dhein S : Increase in gap junction conductance by an antiarrhythmic peptide. Eur J Pharmacol 1997 327 : 65 72.
62. Müller A, Schaefer T, Linke W, Tudyka T, Gottwald M, Klaus W, Dhein S : Actions of the antiarrhythmic peptide AAP10 on intercellular coupling. Naunyn Schmiedebergs Arch Pharmacol 1997 356 : 76 82.
63. Weng S, Lauven M, Schaefer T, Polontchouk L, Grover R, Dhein S : Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation. FASEB J 2002 16 : 1114 1116.
64. Eloff BC, Gilat E, Wan X, Rosenbaum DS : Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: Evidence supporting a novel target for antiarrhythmic therapy. Circulation 2003 108 : 3157 3163.
65. Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J : Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: Comparative efficacy and results of trials. Am J Cardiol 2003 91 : 15D 26D.
66. Gerstenfeld EP, Guerra P, Sparks PB, Hattori K, Lesh MD : Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. J Cardiovasc Electrophysiol 2001 12 : 900 908.
67. Berkowitsch A, Neumann T, Kurzidim K, Reiner C, Kuniss M, Siemon G, Sperzel J, Pitschner HF : Comparison of generic health survey SF-36 and arrhythmia related symptom severity check list in relation to post-therapy AF recurrence. Europace 2003 5 : 351 355.
68. Erdogan A, Carlsson J, Neumann T, Berkowitsch A, Neuzner J, Hamm CW, Pitschner HF : Quality-of-life in patients with paroxysmal atrial fibrillation after catheter ablation: Results of long-term follow-up. Pacing Clin Electrophysiol 2003 26 : 678 684.
69. Chen J, Hoff PI, Erga KS, Rossvoll O, Ohm OJ : A clinical study of patients with and without recurrence of paroxysmal atrial fibrillation after pulmonary vein isolation. Pacing Clin Electrophysiol 2005 28 (Suppl 1 S86 S89.
70. Hohnloser SH, Kuck KH, Lilienthal J : Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000 356 : 1789 1794.
71. Ausma J, Wijffels M, Thoné F, Wouters L, Allessie M, Borgers M : Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997 96 : 3157 3163.